{"filing":{"accession_number":"0001193805-26-000916","cik":"0001280776","ticker":"IMUX","company_name":"IMMUNIC, INC.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"e665619_8k-immunic.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000916/e665619_8k-immunic.htm"},"events":[{"id":17068,"run_id":15281,"accession_number":"0001193805-26-000916","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses two executive changes: Tamar Howson's resignation from the Board and Compensation Committee on June 29, 2026, and Erik Lundgren's appointment as a Class II director on July 5, 2026. While both events are disclosed, the principal action emphasized is Lundgren's appointment to the Board following the Nominating and Corporate Governance Committee's recommendation. The appointment of the CEO to the Board is the forward-looking material event, making exec_appointment the most salient classification.","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":15373,"accession_number":"0001193805-26-000916","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses two executive changes: Tamar Howson's resignation from the Board and Compensation Committee on June 29, 2026, and Erik Lundgren's appointment as a Class II director on July 5, 2026. While both events are disclosed, the principal action emphasized is Lundgren's appointment to the Board following the Nominating and Corporate Governance Committee's recommendation. The appointment of the CEO to the Board is the forward-looking material event, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:49:19.135337+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15373,"accession_number":"0001193805-26-000916","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses two executive changes: Tamar Howson's resignation from the Board and Compensation Committee on June 29, 2026, and Erik Lundgren's appointment as a Class II director on July 5, 2026. While both events are disclosed, the principal action emphasized is Lundgren's appointment to the Board following the Nominating and Corporate Governance Committee's recommendation. The appointment of the CEO to the Board is the forward-looking material event, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:49:19.135337+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-07-06"}]}